The rising interest in successful weight management has led to considerable exploration into cutting-edge treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has exhibited positive results in clinical trials, implying potential for considerable w